A sensitive and specific diagnostic test for Bladder Cancer.
Archer FusionPlex Acute Lymphoblastic Leukemia (ALL)
NGS analysis of relevant regions related to Acute Lymphoblastic Leukemia.
Archer FusionPlex Lymphoma
NGS panel for the study of fusions, point mutations and expression levels in lymphomes.
Archer FusionPlex Myeloid
NGS panel for the study of fusions, point mutations and expression levels in several types of myeloid diseases.
Archer VariantPlex Comprehensive Thyroid & Lung Kit
NGS assay for the study of 31 genes involved in thyroid and lung cancer
Archer VariantPlex Myeloid / Core Myeloid
NGS panels for AML, MPN, MDS and some Lymphoid malignancy markers
Prognostic and predictive molecular in vitro test to determine the risk of recurrence and the absolute benefit of chemotherapy over the next 15 and 10 years, respectively, in patients with ER+/HER2- primary breast cancer.
GeoMx Cancer Transcriptome Atlas (CTA)
Spatial study of the expression of over 1,800 genes involved in tumour biology, tumour microenvironment and immune response.
GeoMx Immune Pathways Panel
The GeoMx® Immune Pathways Panel is designed to profile key aspects of tumor biology, the tumor microenvironment, and the immune response, with spatial resolution from distinct regions of interest with a […]
GeoMx Whole Transcriptome Atlas (WTA)
Comprehensive spatial study of cellular biology, with full coverage of protein coding genes, and application in several fields: oncology, immunology, neuroscience, developmental biology...
LIQUIDPlex ctDNA 28
NGS assay to study 28 genes commonly associated with solid tumor type cancers from circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA).
Mentype® AMLplex – acute myeloid leukemia
Detection of chromosomal aberrations in acute myeloid leukemia (AML).
MiniHRS kit (Mini Homologous Recombination)
Study of 4 genes associated with breast and ovarian cancer.
The most comprehensive tumor test to determine Homologous Recombination Deficiency (HDR) Status by studying the BRCA genes in patients with ovarian cancer.
myChoice CDx PLUS
La prueba más completa para determinar el estado de deficiencia de la recombinación homóloga (HDR) estudiando los genes BRCA y 13 más adicionales, en pacientes con cáncer de ovario.
Myeloid Solution (MYS and MYSplus)
Identification of mutations associated to Myelodysplasic Syndroms, Myeloproliferative Neoplasms and Leukemia.
nCounter Breast Cancer 360 Panel
Expression study of genes involved in breast cancer biology, including tumoral microenvironment and immune response.
nCounter CAR-T Characterization Panel
Study of gene expression aimed at the development of CAR-T cell therapies.
nCounter Metabolic Pathways Panel
Study of genes involved in core metabolic processes and immunometabolism.
nCounter PanCancer Immune Profiling Panel
Comprehensive study of the immune response, optimized for immuno-oncology research, including essential genes for the tumor biology and the tumoral microenvironment.
nCounter PanCancer Immuno-Oncology 360 Panel
Comprehensive study of genes involved in the tumoral immune evasion and the response to immunotherapy, including essential genes for the tumoral microenvironment and the immune response.
nCounter PanCancer Pathways Panel
Comprehensive study of genes involved in major cancer pathways, including essential genes for the tumor biology, the tumoral microenvironment and the immune response.
nCounter PanCancer Progression Panel
Comprehensive study of genes involved in processes and mechanisms related to cancer progression, including essential genes for tumor biology, the tumoral microenvironment and the immune response.
nCounter Tumor Signaling 360 Panel
Comprehensive study of dysfunctional cell signaling in cancer, including essential genes for the tumor biology, the tumoral microenvironment and the immune response.
Nonpolyposis colorectal cancer- HNPCC kit
Microsatellites instability analysis in tumor-associated HNPCC and in sporadic colon and stomach cancer.
Paneles TruSight. Genética y Oncología
Kits based on Next-Generation Sequencing technology for the analysis of multiple genes.
Prognostic test to determine tumour aggressiveness and 10-year disease-specific mortality in patients with primary localised prostate cancer.